1. Complexity
The life sciences industry of today is increasingly complex. Governments are escalating the pressure to make drugs more affordable. The number of new market entrants is on the up. Accelerated clinical trials are shortening drug lifecycles. There is a sharper focus on novel treatments. And the industry is shifting toward patient-centric holistic care.
For example, heightened demand for new treatments such as gene and cell therapies, RNA interference, and endogenous metabolic modulators, has led some companies to deprioritize and even divest current assets dedicated to small molecule drug development in favor of more complex large molecules and advancing medical …
